Diakonos Oncology CFO Anthony Baldor to Update at BIO International Convention, June 3-6, 2024

Diakonos Oncology Corp., a clinical-stage biotechnology company specializing in immuno-oncology, has announced that its Chief Financial Officer and Head of Business Development, Anthony Baldor, will present at the 2024 BIO International Convention, scheduled for June 3-6, 2024, in San Diego. The presentation is set for June 4 at 3 pm PT in Company Presentation Theater 2, located at the San Diego Convention Center.

In his presentation, Mr. Baldor will provide an in-depth review of Diakonos’ innovative autologous dendritic cell vaccines designed for cancer treatment. This will include sharing clinical data and offering an operational update on the company's growth strategies. Key topics will include the company's progress in clinical development and plans to expand the leadership team.

A significant highlight of the presentation will be the recent completion of a Phase 1 trial of Diakonos' leading vaccine, DOC1021, intended for treating glioblastoma multiforme (GBM). Following the promising results of the Phase 1 trial, the company is now gearing up for a Phase 2 study. The US Food and Drug Administration has recognized the potential of DOC1021 by granting it Fast Track and Orphan Drug status, highlighting its importance in the treatment of this aggressive cancer.

Apart from the DOC1021 vaccine for GBM, Diakonos is also conducting clinical trials for dendritic cell vaccines targeting pancreatic cancer and angiosarcoma. The results of the Phase 1 trial for GBM are particularly encouraging, with a 12-month survival rate currently at 90% for patients who can be evaluated. The therapy has also been well tolerated, which adds to the optimism surrounding the treatment’s potential.

Diakonos’ dendritic cell vaccines work by activating robust cytotoxic TH1 cell signaling pathways. This mechanism allows the patient's immune system to effectively target and eliminate cancer cells through a natural immune response. One of the significant advantages of this approach is that it does not involve any genetic modification of the patient's immune cells. This not only simplifies the manufacturing process but also substantially reduces costs compared to other leading cell therapy methods.

Headquartered in Houston, Texas, Diakonos Oncology is committed to advancing cancer immunotherapy, particularly for hard-to-treat cancers such as glioblastoma. The DOC1021 treatment platform is also being tested in early-stage clinical trials for pancreatic ductal adenocarcinoma (PDAC) and cutaneous angiosarcoma (AS).

The announcement of Mr. Baldor’s presentation at the BIO International Convention underscores Diakonos' ongoing efforts to communicate its progress and future plans to a broader audience, including potential partners, investors, and the scientific community. The company remains dedicated to its mission of revolutionizing cancer treatment through its pioneering dendritic cell vaccine technology.

Diakonos’ approach could mark a significant shift in the landscape of cancer treatment, offering new hope for patients with some of the most challenging cancer diagnoses. As the company prepares for its next phase of clinical trials and continues to develop its innovative therapies, the upcoming presentation will be a pivotal moment in sharing their achievements and future direction with the world.